PURPOSE: To determine whether higher physical activity after prostate cancer (PCa) diagnosis decreases risk of overall and PCa-specific death. PATIENTS AND METHODS: We evaluated physical activity in relation to overall and PCa mortality among 2,705 men in the Health Professionals Follow-Up Study diagnosed with nonmetastatic PCa observed from 1990 to 2008. Proportional hazards models were used to evaluate physical activity and time to overall and PCa-specific death. RESULTS: Among men who lived at least 4 years after their postdiagnosis physical activity assessment, we documented 548 deaths, 20% of which were a result of PCa. In multivariable analysis, men who were physically active had lower risk of all-cause mortality (P(trend) < .001) and PCa mortality (P(trend) = .04). Both nonvigorous activity and vigorous activity were associated with significantly lower overall mortality. Those who walked ≥ 90 minutes per week at a normal to very brisk pace had a 46% lower risk of all-cause mortality (hazard ratio [HR] 0.54; 95% CI, 0.41 to 0.71) compared with shorter durations at an easy walking pace. Men with ≥ 3 hours per week of vigorous activity had a 49% lower risk of all-cause mortality (HR, 0.51; 95% CI, 0.36 to 0.72). For PCa-specific mortality, brisk walking at longer durations was suggestively inverse but not statistically significant. Men with ≥ 3 hours per week of vigorous activity had a 61% lower risk of PCa death (HR, 0.39, 95% CI, 0.18 to 0.84; P = .03) compared with men with less than 1 hour per week of vigorous activity. Men exercising vigorously before and after diagnosis had the lowest risk. CONCLUSION: In men with PCa, physical activity was associated with lower overall mortality and PCa mortality. A modest amount of vigorous activity such as biking, tennis, jogging, or swimming for ≥ 3 hours a week may substantially improve PCa-specific survival.
PURPOSE: To determine whether higher physical activity after prostate cancer (PCa) diagnosis decreases risk of overall and PCa-specific death. PATIENTS AND METHODS: We evaluated physical activity in relation to overall and PCa mortality among 2,705 men in the Health Professionals Follow-Up Study diagnosed with nonmetastatic PCa observed from 1990 to 2008. Proportional hazards models were used to evaluate physical activity and time to overall and PCa-specific death. RESULTS: Among men who lived at least 4 years after their postdiagnosis physical activity assessment, we documented 548 deaths, 20% of which were a result of PCa. In multivariable analysis, men who were physically active had lower risk of all-cause mortality (P(trend) < .001) and PCa mortality (P(trend) = .04). Both nonvigorous activity and vigorous activity were associated with significantly lower overall mortality. Those who walked ≥ 90 minutes per week at a normal to very brisk pace had a 46% lower risk of all-cause mortality (hazard ratio [HR] 0.54; 95% CI, 0.41 to 0.71) compared with shorter durations at an easy walking pace. Men with ≥ 3 hours per week of vigorous activity had a 49% lower risk of all-cause mortality (HR, 0.51; 95% CI, 0.36 to 0.72). For PCa-specific mortality, brisk walking at longer durations was suggestively inverse but not statistically significant. Men with ≥ 3 hours per week of vigorous activity had a 61% lower risk of PCa death (HR, 0.39, 95% CI, 0.18 to 0.84; P = .03) compared with men with less than 1 hour per week of vigorous activity. Men exercising vigorously before and after diagnosis had the lowest risk. CONCLUSION: In men with PCa, physical activity was associated with lower overall mortality and PCa mortality. A modest amount of vigorous activity such as biking, tennis, jogging, or swimming for ≥ 3 hours a week may substantially improve PCa-specific survival.
Authors: Jeffrey A Meyerhardt; Edward L Giovannucci; Shuji Ogino; Gregory J Kirkner; Andrew T Chan; Walter Willett; Charles S Fuchs Journal: Arch Intern Med Date: 2009-12-14
Authors: Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci Journal: Int J Cancer Date: 2009-06-01 Impact factor: 7.396
Authors: Barbara J Nicklas; Fang-Chi Hsu; Tina J Brinkley; Timothy Church; Bret H Goodpaster; Stephen B Kritchevsky; Marco Pahor Journal: J Am Geriatr Soc Date: 2008-11 Impact factor: 5.562
Authors: Nina Føns Johnsen; Anne Tjønneland; Birthe L R Thomsen; Jane Christensen; Steffen Loft; Christine Friedenreich; Timothy J Key; Naomi E Allen; Petra H Lahmann; Lotte Mejlvig; Kim Overvad; Rudolf Kaaks; Sabine Rohrmann; Heiner Boing; Gesthimani Misirli; Antonia Trichopoulou; Dimosthenis Zylis; Rosario Tumino; Valeria Pala; H Bas Bueno-de-Mesquita; Lambertus A Kiemeney; Laudina Rodríguez Suárez; Carlos A Gonzalez; Maria-José Sánchez; José María Huerta; Aurelio Barricarte Gurrea; Jonas Manjer; Elisabet Wirfält; Kay-Tee Khaw; Nick Wareham; Paolo Boffetta; Lars Egevad; Sabina Rinaldi; Elio Riboli Journal: Int J Cancer Date: 2009-08-15 Impact factor: 7.396
Authors: M A Liss; J M Schenk; A V Faino; L F Newcomb; H Boyer; J D Brooks; P R Carroll; A Dash; M D Fabrizio; M E Gleave; P S Nelson; M L Neuhouser; J T Wei; Y Zheng; J L Wright; D W Lin; I M Thompson Journal: Prostate Cancer Prostatic Dis Date: 2016-07-19 Impact factor: 5.554
Authors: Siobhan M Phillips; Meir J Stampfer; June M Chan; Edward L Giovannucci; Stacey A Kenfield Journal: J Cancer Surviv Date: 2015-04-16 Impact factor: 4.442
Authors: Erin L Van Blarigan; John P Gerstenberger; June M Chan; Lorelei A Mucci; Stacey A Kenfield; Edward L Giovannucci; Meir J Stampfer; Lee W Jones; Steven K Clinton Journal: Cancer Prev Res (Phila) Date: 2015-08-14
Authors: Dori Rosenberg; Elyse A Kadokura; Erin D Bouldin; Christina E Miyawaki; Celestia S Higano; Andrea L Hartzler Journal: AMIA Annu Symp Proc Date: 2017-02-10
Authors: Daniel Santa Mina; Michael K Connor; Shabbir M H Alibhai; Paul Toren; Crissa Guglietti; Andrew G Matthew; John Trachtenberg; Paul Ritvo Journal: Can Urol Assoc J Date: 2013 Nov-Dec Impact factor: 1.862
Authors: Ashley Bigaran; Eva Zopf; Jason Gardner; Andre La Gerche; Declan G Murphy; Erin J Howden; Michael K Baker; Prue Cormie Journal: Prostate Cancer Prostatic Dis Date: 2020-08-28 Impact factor: 5.554